Dendritic Cell Vaccines
Dendritic cells (DCs) break the antigens on the cancer cell surfaces into smaller pieces. The dendritic cells then act as most-wanted posters for the immune system, displaying those antigen pieces to the killer T cells. Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for dendritic cell-based vaccines. We guarantee the finest results for our customers all over the world.
DCs originate from the bone marrow, and their precursors migrate via the bloodstream to almost all organs of the body, where they reside as immature cells with high phagocytic capacity. They acquire antigens (Ag) in peripheral tissues and migrate to lymphoid organs where they present processed peptides to naive T cells and initiate the immune response. During this process, DCs lose their Ag-capturing/processing capacity as they differentiate into mature, fully stimulatory, antigen-presenting cells. In addition, DCs interact with B lymphocytes to enhance B cell expansion and antibody production, as well as with natural killer (NK) cells to augment cytolytic activity and interferon-γ (IFN-γ) production.
In order to make dendritic cell vaccines some of the patient's dendritic cells are extracted and immune cell stimulants are used to reproduce large amounts of dendritic cells in the lab. These dendritic cells are then exposed to antigens from the patient's cancer cells. This combination of dendritic cells and antigens is then injected into the patient and the dendritic cells work to program the T cells.
Fig.1 A general workflow for the production of autologous dendritic cell vaccines for cancer. [1]
Experimental Animal Models
Creative Biolabs provides experimental animal models to assist our customers with dendritic cell vaccines studies.
Mouse bone marrow is a major source of DCs when cultivated with granulocytemacrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4. Most published reports of mouse DCs use cells derived from BALB/c or C57Bl/6 mice. In general, mice 8–12 weeks old yield sufficient numbers of DCs, precursor, and progenitor cells to be easily manipulated. Typical DC yields are approximately 5 × 106 cells/mouse. Further maturation of DCs can be achieved by LPS or TNF-α treatment.
DC-Based Vaccination in Animal Tumor Models
A growing number of studies have reported the successful use of DCs for inducing antitumor immune responses in animals. Most of these experiments have involved in vitro isolation of DCs, followed by pulsing of DCs with different forms of tumor antigen and injection of the antigen-loaded DCs into syngeneic animals as a cancer vaccine. Tumor development was induced by injection of established tumor cell lines of various tissue origins. Following interaction with tumor cells or selected tumor Ags, DCs were effective as prophylactic tumor vaccines against subsequent challenge with the same tumor. Initial approaches using DCs loaded with tumor lysates, tumor antigen-derived peptides, soluble protein tumor antigen expressed by a B cell lymphoma, synthetic class I-MHC-restricted peptides, RNA, DNA and whole protein have all been demonstrated to generate tumor-specific immune responses and antitumor activity against subsequent tumor challenges, and even therapeutic efficacy was reported, leading to the induction of regression of preexisting tumors.
Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.
Reference
- Surmont, VF. (2011). “Investigational approaches for mesothelioma.” Front Oncol 1, 22.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
